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A Rare Care of a Non- Functioning Pancreatic Neuroendocrine Tumor in a Young Female
Neethi Dasu
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INTRODUCTION
• Pancreatic neuroendocrine tumors (PNETs) are
very rare and represent about 1–2% of all
pancreatic tumors.
• Non-functional PNETs (NF-PNETs) represent
approximately 85% of all PNETs. They are
mostly found incidentally at an advanced stage
because patients are asymptomatic and the
tumors do not secrete hormones that would
manifest with symptoms.
• More than 95 percent of the pancreatic
neoplasms arise from the exocrine component
of the pancreas. Neoplasms arising from the
endocrine pancreas are neuroendocrine
tumors (NETs).
• PNETs, also known as islet cell tumors,
originate in the islets of Langerhans. PNETs are
rare neoplasms of the pancreas, with an
incidence of 1/100,000/year and account for
about 1-2% of all pancreatic neoplasms [2].
• Computed tomography (CT) is the imaging
modality of choice, but other diagnostic
imaging tools need to be investigated for
earlier detection of this insidious and fatal
disease.
• Surgical treatment is currently preferred, but
only palliative chemotherapy and radiation is
currently available for advanced disease.
• We report a case of 32-yr-old female who
initially presented with increasing abdominal
girth, decreased mobility, and lower extremity
swelling up to the hip and she was incidentally
found to have a widely metastatic
intermediate grade NF-PNET stage IV T2N0M1
to the liver, peritoneum, bones, and
gallbladder.
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CASE REPORT
• This is a case of a young female who
underwent a computed tomography of the
abdomen and pelvis (CT) in 2016 that showed
a massively enlarged liver with diffuse
metastases and her largest lesion measured
5.8x4.9cm.
• The patient also had a 3.5x3.6 cm pancreatic
tail mass as well as a 10.3x11 cm mass in her
pelvic areas extending to the vaginal wall:

• The patient underwent a core biopsy of her
liver on 01/28/2016 and her pathology
showed a metastatic neuroendocrine tumor
with Ki 67 of 40% and a mitotic rate of 10 per
10 HPF.
• Treatment with capecitabine and
temozolomide began shortly after.
• A repeat CT of the abdomen and pelvis on
06/24/2016 showed significant decrease in
her pancreatic mass and liver metastases.
• Chromogranin A level had decreased from
5800 to 35 ng/dL. She completed 6 cycles of
chemotherapy and then had an exploratory
laparotomy, lysis of adhesions, and bilateral
oopherectomy with the gynecology service.
• The patient was found to have metastatic
disease with peritoneal deposits to her
sigmoid colon and her peritoneum. Her
treatment was changed to octreotide and
everolimus postoperatively until

the MRI of her abdomen in mid 2017 showed
progression of liver metastases.
• The patient was then changed to
doxorubicin, 5-fluorouracil (5-FU), and
streptozocin.
• Repeat imaging showed improvement of her
metastases to the liver.
• The patient received four cycles of treatment
and she then received Y90 to her liver that
completed in early 2018.
• A repeat MRI of the abdomen showed stable
disease in her liver.
• A bone scan shortly after showed multiple
bone lesions and she was having significant
bone pain. She received one cycle of
platinum and etoposide and she felt that her
bone pain was improving.
• A gallium 68 PET CT was recommended to
clarify if the patient had an overexpression of
somatostatin receptors and this would be
more consistent with a slower growing NET.
The patient would then receive treatment
with Peptide Receptor Radionuclide Therapy
(PRRT).
• The patient was diagnosed with widely
metastatic intermediate grade NF-PNET stage
IV T2N0M1 to the liver, peritoneum, bones,
and gallbladder.

DISCUSSION
• According to the World Health Organization
(WHO) classification, three classes of NETs
can be identified based on histology and
pathology: well-differentiated NETs can be
classified as G1 tumors, when they express
<2 mitoses/10 HPF and ≤2% Ki-67 index;

as G2 tumors, when they express 2-20
mitoses/10 HPF and 3-20% Ki-67, whereas
neuroendocrine carcinomas (NECs) usually
belong to G3 category, with >20 mitoses/10 HPF
and >20% Ki-67 index [1].
• The patient had Ki 67 of 40%.
• Potential risk factors for PNETs include
diabetes, smoking, a previous history of
chronic pancreatitis, and genetic factors
(hereditary endocrinopathies, including
multiple endocrine neoplasia types I) [2],
However the patient had no risk factors for
this disease.
• Clinical management involves a
multidisciplinary approach, but surgery
remains the only curative therapy for earlystage disease.
• Radical surgery for pancreatic NET offers a 5year survival rate of 45-92%, highlighting the
importance of accurate diagnosis and
appropriate referral of patients for surgery [3].

CONCLUSION
• Because of its rarity, randomized controlled
studies have not been done and current
treatment recommendations are based
primarily on case series and individual
treatment approaches [4].
• Further research is under way on newer,
investigational drugs.
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